Respiratory syncytial virus: Infectious substances pathogen safety data sheet

For more information on Respiratory syncytial virus, see Respiratory syncytial virus (RSV).

Section I: Infectious agent


Respiratory syncytial virus

Agent type








Orthopneumovirus hominis

Synonym or cross-reference

Respiratory syncytial virus is also known as human respiratory syncytial virus (hRSV), pneumovirus, and human orthopneumovirus.


Brief description

Respiratory syncytial virus (RSV) is classified as a member of the genus Pneumovirus in the family PneumoviridaeFootnote 1,Footnote 2,Footnote 3,Footnote 4. The viral genome consists of a linear, single-stranded, negative-sense, non-segmented RNA (~15.2 kb). RSV lacks haemagglutinin and neuraminidase activity. Virus particles are enveloped and pleomorphic, occurring as irregular spherical particles that are 100 to 350 nm in diameter, and as long filamentous fibres that are 60 to 200 nm in diameter and 10 µm in lengthFootnote 2. The virion consists of nine structural proteinsFootnote 1,Footnote 2,Footnote 3,Footnote 4,Footnote 5. Three proteins are associated with the nucleocapsid and include nucleoprotein (N), phosphoprotein (P), and polymerase or large protein (L). The other six viral proteins are contained within the virus envelope and include nonglycosylated matrix protein (M), M2 (M2-1 and M2-2), fusion protein (F), glycoprotein (G), and short hydrophobic protein (SH)Footnote 1,Footnote 2,Footnote 3,Footnote 4,Footnote 6,Footnote 7. There are two non-structural proteins, NS-1 and NS-2, which are involved in innate immune response evasionFootnote 6,Footnote 7. RSV can be divided into two subtypes, A and B, based on variations in the G proteinFootnote 8. The predominance of these subtypes alternates during different epidemic seasons however there is no difference in severityFootnote 8.


RSV has an RNA genome, thus its replication is RNA-dependent and it lacks proofreading mechanismsFootnote 7. This leads to many single nucleotide polymorphism (SNP) errors and other mutations. The constant change in the genome allows for changes in virulence and makes it difficult to develop vaccines and antiviral agents.

Section II: Hazard identification

Pathogenicity and toxicity

RSV primarily infects human epithelial cells within the nasopharynx; however, it can also infect other types of cells, including cell lines, but with much lower efficacyFootnote 1, Footnote 2. Infection may lead to the formation of syncytia within the infected cell. Primary infection with RSV is generally exhibited as lower respiratory tract disease, pneumonia, bronchiolitis, tracheobronchitis, or upper respiratory tract illnessFootnote 1,Footnote 2,Footnote 3,Footnote 4. In infants, RSV infection causes approximately 70% of viral bronchiolitis casesFootnote 6. Common clinical symptoms include rhinorrhea, sneezing, coughing, pharyngitis, bronchitis, headache, fatigue, chest tightness, wheezing, dyspnea, and feverFootnote 1,Footnote 2,Footnote 3,Footnote 4,Footnote 5. In some cases, otitis media may occurFootnote 4. RSV infections usually begin with upper respiratory tract disease, which has the tendency to progress to lower respiratory tract disease (in ~50% cases)Footnote 1,Footnote 2. Symptoms begin 3-7 days post infection with RSVFootnote 5. Healthy individuals typically recover in 1-2 weeks, but it can take much longer if serious disease developsFootnote 9. RSV can cause long term-effects Footnote 10,Footnote 11. Approximately half of the infants experience recurrent wheezing following RSV lower respiratory tract infection. Wheezing symptoms can persist for up to 5 years followed by a gradual decrease.


RSV occurs worldwide and is the most common cause of bronchiolitis and pneumonia among infants and young childrenFootnote 1,Footnote 2,Footnote 3,Footnote 4. Within the United States, hospitalizations due to RSV have increased significantly in 2022 in comparison to previous yearsFootnote 13. As of November 2022, the overall rate of RSV-associated hospitalizations is 18 per 100,000 people. It is estimated that there are 33 million cases of lower respiratory infections attributed to RSV annually on a global scaleFootnote 11. Of those cases, 3 million infections led to hospitalization and approximately 60,000 resulted in death. 99% of RSV-related deaths occur in developing countriesFootnote 6,Footnote 11. RSV is also a major cause of nosocomial infections. Morbidity and mortality are highest among children with underlying illness and individuals with immunodeficiency or immunosuppression. Virtually all children are infected by age 2 to 3Footnote 1,Footnote 2,Footnote 3. Repeated infections are common, particularly in young children with up to 5 or 6 infections per yearFootnote 4. Although all individuals can be infected with RSV, those at high risk include premature infants, young children, particularly those under age 2 with chronic lung conditions, elderly populations, and immunocompromised individualsFootnote 1,Footnote 2, Footnote 3, Footnote 4. Other factors that may predispose an individual to RSV infection include: crowding (schools and day care centers), exposure to tobacco and smoke, low socioeconomic status, and family history of atopy and asthma. The presence of older siblings is also a risk factorFootnote 6. Infection among healthy and immunocompetent individuals tends to be less severe. RSV follows a seasonal patternFootnote 1,Footnote 2. Annual outbreaks occur during fall, winter, and early spring among urban centres. In the Northern hemisphere, outbreaks peak in February and March, and may last up to 5 months. In tropical and subtropical regions, most outbreaks occur during the rainy season. RSV outbreaks involving lower respiratory illness have been reported in nursing homes and institutionsFootnote 1.

Age is the largest risk factor, with RSV infection being most prominent and severe in young children and elderly personsFootnote 6. Infection is also more prevalent in males. Severe infection (involving pneumonia) may develop among elderly patients with underlying respiratory conditionsFootnote 1,Footnote 2. Children and immunocompromised individuals are more susceptible to developing severe disease. Comorbidities that increase the risk of RSV infection include low birthweight, immunologic disorders, genetic abnormalities, pulmonary disease, neoplasia, and defects of heart and/or lung structuresFootnote 7. Transplant recipients have a higher mortality rate of RSV infection than the general population.

Host range

Natural host(s)

HumansFootnote 1,Footnote 2.

Other host(s)

Various animal species have been experimentally infected with RSV, including cotton rats, mice, ferrets, guinea pigs, hamsters, marmosets, lambs, and nonhuman primates Footnote 2.

Infectious dose

The infectious dose for RSV is > 160 - 640 viral units, administered through intranasal spray, as listed by the National Institutes of HealthFootnote 14. An intranasal dose of 106 plaque-forming units (pfu) of RSV type B causes infection in over 50% of participantsFootnote 15. After intranasal administration of 5.0 × 102 pfu of RSV A2, 100% of male participants experienced infection without overt disease.

Incubation period

Incubation period for RSV infection ranges from 2 to 8 daysFootnote 1. RSV is shed during the period of active disease and can continue for over 20 days after clinical recoveryFootnote 12.


RSV is most likely transmitted through direct contact with infectious secretions (via fomites) and/or large-particle aerosolsFootnote 1,Footnote 2; however, close contact with infected individuals, or significant exposure of nasal or conjunctival mucosa with contaminated hands is required for transmissionFootnote 2. Transmission via small-particle aerosols is less likelyFootnote 1, Footnote 2.

RSV is communicable during the period of active disease, and for as long as a month afterFootnote 12. Children especially are known to shed virus for long periods even after clinical recoveryFootnote 1,Footnote 2. The disease is not readily transmitted from person-to-person, since significant and prolonged contact is required with infected individualsFootnote 1.

Section III: Dissemination


HumansFootnote 1,Footnote 16.


NoneFootnote 16.



Section IV: Stability and viability

Drug susceptibility/resistance

RSV has been shown to be susceptible to ribavirin, which has been used to treat severe RSV infections; however, recent studies suggest that its use produces no significant benefitFootnote 1, Footnote 2, Footnote 4. Palivizumab is licensed for RSV prophylaxis and is commonly used to prevent infection for high-risk infants and individuals with cardiopulmonary disordersFootnote 5,Footnote 6,Footnote 7. It is administered monthly via intramuscular injectionFootnote 6. There are several experimental antiviral strategies under developmentFootnote 7.

RSV strains resistant to palivizumab have been identified in experimental modelsFootnote 7.

Susceptibility to disinfectants

RSV has been shown to be susceptible to ether, chloroform, and a variety of detergents, including 0.1% sodium deoxycholate, sodium dodecyl sulphate, and Triton X-100Footnote 1. It may also be sensitive to hypochlorites (1% sodium hypochlorite), formaldehyde (18.5 g/L; 5% formalin in water), 2% glutaraldehyde, and iodophores (1% iodine)Footnote 17. Diluted isopropanol (35%) reduces the infectivity of RSVFootnote 18. Other agents effective against RSV include Lysol, povidone-iodine, Amphyl, Hibiclens, O-syl, ethanol, and ListermintFootnote 19.

Physical inactivation

RSV is sensitive to heating above 55°C for 5 minutes (up to 90% decrease in infectivity)Footnote 1. It is also sensitive to freezing and thawing (~90% loss in infectivity following each freeze-thaw cycle). It is also sensitive to acidic media (pH<7).

Survival outside host

RSV is generally very vulnerable to environmental changes, particularly temperature and humidityFootnote 1. It is sensitive to high and low temperatures and to drying (i.e., low humidity levels). It loses up to 90% infectivity at room temperature after 48 hours and up to 99% at 1°C after 7 daysFootnote 1. The optimal pH is 7.5. It may survive for about 3 to 30 hours on nonporous surfaces at room temperature. RSV can be recovered from countertops for up to 7 hours, from rubber gloves for 5 hours, from cloth material for 2 hours, and from skin for up to 20 minutesFootnote 20. Survival times decrease slightly in higher temperature environments.

Section V: First aid/medical


RSV can be detected by monitoring for symptomsFootnote 4. There are four main laboratory techniques for diagnosing RSV, including virus cultures, serology, immunofluorescence and/or antigen detection, and nucleic acid-based tests. Being labour-intensive and time consuming, the first two techniques are rarely employed for diagnostic purposes in epidemiological studies. Rapid diagnostic techniques for viral antigen detection, including immunofluorescent-antibody assay, optical immunoassay, enzyme immunoassay, and chromatographic immunoassay are preferred as most are commercially available, easy to perform and produce rapid resultsFootnote 1. Direct fluorescent antibody testing is useful in high-risk patients and produces a rapid response, however, the sensitivity decreases in adult patientsFootnote 7. Nucleic acid tests (such as RT-PCR) are generally more sensitiveFootnote 4. A three-tube reverse transcription-PCR (RT-PCR) assay is in development which would enable simultaneous detection of nine respiratory pathogens including RSVFootnote 21.

Note: The specific recommendations for surveillance in the laboratory should come from the medical surveillance program, which is based on a local risk assessment of the pathogens and activities being undertaken, as well as an overarching risk assessment of the biosafety program as a whole. More information on medical surveillance is available in the Canadian Biosafety Handbook (CBH).

First aid/treatment

Treatment is mainly supportive for infants with mild disease; however, children with severe disease, people with underlying illness, and/or immunocompromised individuals may require hospitalizationFootnote 1,Footnote 2,Footnote 4. There are currently two antivirals for RSV available, ribavirin for treatment and palivizumab for preventionFootnote 7. Aerosolized ribavirin may be administered to immunocompromised patients with severe illness; however, recent studies suggest that its use produces no significant benefitFootnote 1,Footnote 2. Palivizumab prophylactic treatment, in combination with aerosolized ribavirin, may also be considered for high-risk children. Inhaled nanobodies are being studied in clinical trials for RSV treatmentFootnote 7. There are several other antiviral strategies in experimental stages. Another approach is to consider the use of anti-inflammatory drugs; however, their overall efficacy is yet to be determinedFootnote 4. Berberine, an anti-inflammatory drug, has been shown to have potential as a therapeutic drug for RSV induced respiratory infection, although its underlying mechanisms are unclearFootnote 22.

Note: The specific recommendations for first aid/treatment in the laboratory should come from the post-exposure response plan, which is developed as part of the medical surveillance program. More information on the post-exposure response plan can be found in the CBH.


No vaccine is currently available; however, there are several vaccines being developedFootnote 7. The Novavax vaccine has completed Phase II clinical trialFootnote 7. There are five subunit vaccines in Phase I trials and one in a Phase II trialFootnote 6.

Note: More information on the medical surveillance program can be found in the CBH, and by consulting the Canadian Immunization Guide.


Palivizumab prophylactic treatment has been shown to reduce the rate of hospitalization in children by up to 55%; however, convincing results on its therapeutic efficacy following an infection have not been observedFootnote 1,Footnote 2,Footnote 4. Palivizumab is a humanized monoclonal antibody that is administered intramuscularly as prophylaxis to high-risk infants for RSV infectionFootnote 7. Other monoclonal antibodies are in preclinical development and preclinical trialsFootnote 5. Aerosolized ribavirin may be administered to immunocompromised patients with severe illness and can be used in combination with palivizumab prophylactic treatmentFootnote 1,Footnote 2.

Note: More information on prophylaxis as part of the medical surveillance program can be found in the CBH.

Section VI: Laboratory hazard

Laboratory-acquired infections

One case of laboratory-acquired infection with RSV was reported before 1976Footnote 23. In a review of laboratory-acquired infections in Canada from 2016 to 2021, RSV was not identifiedFootnote 24.

Note: Please consult the (CBS) and CBH for additional details on requirements for reporting exposure incidents. A Canadian biosafety guideline describing notification and reporting procedures is also available.


The main sources for RSV include saliva, mucous droplets, nasal secretions, nasal swabs, nasopharyngeal swabs, and nasopharyngeal aspiratesFootnote 1,Footnote 4,Footnote 5.

Primary hazards

Droplet or aerosol exposure of mucous membranes and accidental inoculation are the primary hazards associated with exposure to RSVFootnote 2.

Special hazards


Section VII: Exposure controls/personal protection

Risk group classification

RSV is a Risk Group 2 Human Pathogen and Risk Group 1 Animal PathogenFootnote 25.

Containment requirements

Containment Level 2 facilities, equipment, and operational practices outlined in the CBS for work involving infectious or potentially infectious materials, animals, or cultures.

Protective clothing

The applicable Containment Level 2 requirements for personal protective equipment (PPE) and clothing outlined in the CBS are to be followed. At minimum, use of a lab coat and closed-toe cleanable shoes, gloves when direct skin contact with infected materials or animals is unavoidable, and eye protection where there is a known or potential risk of exposure to splashes.

Note: A local risk assessment will identify the appropriate hand, foot, head, body, eye/face, and respiratory protection, and the personal protective equipment requirements for the containment zone and work activities must be documented.

Other precautions

A biological safety cabinet (BSC) or other primary containment devices to be used for activities with open vessels, based on the risks associated with the inherent characteristics of the regulated material, the potential to produce infectious aerosols or aerosolized toxins, the handling of high concentrations of regulated materials, or the handling of large volumes of regulated materials.

Use of needles and syringes is to be strictly limited. Bending, shearing, re-capping, or removing needles from syringes is to be avoided, and if necessary, performed only as specified in standard operating procedures (SOPs). Additional precautions are required with work involving animals or large-scale activities.

For diagnostic laboratories handling primary specimens that may contain RSV, the following resources may be consulted:

Section VIII: Handling and storage


Allow aerosols to settle. Wearing personal protective equipment, gently cover the spill with absorbent paper towel and apply suitable disinfectant, starting at the perimeter and working towards the centre. Allow sufficient contact time with the disinfectant before clean up (CBH).


All materials/substances that have come in contact with the regulated material should be completely decontaminated before they are removed from the containment zone or standard operating procedures (SOPs) to be in place to safely and securely move or transport waste out of the containment zone to a designated decontamination area / third party. This can be achieved by using decontamination technologies and processes that have been demonstrated to be effective against the regulated material, such as chemical disinfectants, autoclaving, irradiation, incineration, an effluent treatment system, or gaseous decontamination (CBH).


Containment Level 2: The applicable Containment Level 2 requirements for storage outlined in the CBS are to be followed. Primary containers of regulated materials removed from the containment zone to be labelled, leakproof, impact resistant, and kept either in locked storage equipment or within an area with limited access.

Section IX: Regulatory and other information

Canadian regulatory information

Controlled activities with respiratory syncytial virus require a Human Pathogens and Toxins Licence issued by the Public Health Agency of Canada. Respiratory syncytial virus is a non-indigenous animal pathogen in Canada; therefore, its importation requires an import permit, issued by the Canadian Food Inspection Agency.

The following is a non-exhaustive list of applicable designations, regulations, or legislations:

Last file update

November, 2022

Prepared by

Centre for Biosecurity, Public Health Agency of Canada.


The scientific information, opinions, and recommendations contained in this Pathogen Safety Data Sheet have been developed based on or compiled from trusted sources available at the time of publication. Newly discovered hazards are frequent and this information may not be completely up to date. The Government of Canada accepts no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information.

Persons in Canada are responsible for complying with the relevant laws, including regulations, guidelines and standards applicable to the import, transport, and use of pathogens in Canada set by relevant regulatory authorities, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment and Climate Change Canada, and Transport Canada. The risk classification and related regulatory requirements referenced in this Pathogen Safety Data Sheet, such as those found in the Canadian Biosafety Standard, may be incomplete and are specific to the Canadian context. Other jurisdictions will have their own requirements.

Copyright© Public Health Agency of Canada, 2023, Canada


Footnote 1

Tang, Y. W., & Crowe JR, J. E. 2011. Respiratory Syncytial Virus and Human Metapneumovirus. Versalovic, K.C. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry and D.W. Warnock (Eds.), Manual of Clinical Microbiology (10th ed., pp. 1357-1371). Washington, USA: ASM Press.

Return to footnote 1 referrer

Footnote 2

Collins, P. L., & Crowe JR, J. E. 2007. Respiratory Syncytial Virus and Metapneumovirus. D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus (Eds.), Fields Virology (5th ed., pp. 1601-1636). Philadelphia, USA: Lippincott Williams & Wilkins.

Return to footnote 2 referrer

Footnote 3

Ogra, P. L. 2004. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatric Respiratory Reviews, 5 Suppl A, S119-26.

Return to footnote 3 referrer

Footnote 4

Tregoning, J. S., & Schwarze, J. 2010. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clinical Microbiology Reviews, 23 (1), 74-98.

Return to footnote 4 referrer

Footnote 5

Shang, Z., S. Tan, and D. Ma. 2021. Respiratory syncytial virus: From pathogenesis to potential therapeutic strategies. Int. J. Biol. Sci. 17:4073-4091.

Return to footnote 5 referrer

Footnote 6

Coultas, J. A., R. Smyth, and P. J. Openshaw. 2019. Respiratory syncytial virus (RSV): A scourge from infancy to old age. Thorax.

Return to footnote 6 referrer

Footnote 7

Griffiths, C., S. J. Drews, and D. J. Marchant. 2017. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. Clin. Microbiol. Rev. 30:277-319.

Return to footnote 7 referrer

Footnote 8

Ciarlitto, C., Vittucci, A.C., Antilici, L. et al. 2019. Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy. Ital J Pediatr 45, 115.

Return to footnote 8 referrer

Footnote 9

Borchers, A. T., C. Chang, M. E. Gershwin, and L. J. Gershwin. 2013. Respiratory syncytial virus - A comprehensive review. Clin. Rev. Allergy Immunol. 45:331-379.

Return to footnote 9 referrer

Footnote 10

Bont, L., W. M. C. Van Aalderen, and J. L. L. Kimpen. 2000. Long-term consequences of Respiratory Syncytial Virus (RSV) bronchiolitis. Paediatr. Respir. Rev. 1:221-227.

Return to footnote 10 referrer

Footnote 11

Kneyber, M. C. J., E. W. Steyerberg, R. de Groot, and H. A. Moll. 2000. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: A quantitative review. Acta Paediatr. Int. J. Paediatr. 89:654-660.

Return to footnote 11 referrer

Footnote 12

Walsh, E. E., D. R. Peterson, A. E. Kalkanoglu, F. E. -. Lee, and A. R. Falsey. 2013. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J. Infect. Dis. 207:1424-1432.

Return to footnote 12 referrer

Footnote 13

Centers for Disease Control and Prevention (CDC). 2022. RSV-NET: Respiratory Syncytial Virus Hospitalization Surveillance Network. 2022:.

Return to footnote 13 referrer

Footnote 14

Collins, C. H., & Kennedy, D. A. 1999. Exposure, sources and route of infection. Laboratory-acquired Infection: History, incidence, causes and preventions (pp. 38-53). Oxford, UK: Butterworth-Heinemann.

Return to footnote 14 referrer

Footnote 15

Yezli, S., and J. A. Otter. 2011. Minimum Infective Dose of the Major Human Respiratory and Enteric Viruses Transmitted Through Food and the Environment. Food Environ. Virol. 3:1-30.

Return to footnote 15 referrer

Footnote 16

Krauss, H., Weber, A., Appel, M., Enders, B., Isenberg, H. D., Schiefer, H. D., Slenczka, W., Graevenitz, A., & Zahner, H. 2003. Viral Zoonoses. Zoonoses: Infectious Disease Transmissible from Animals to Humans (3rd ed., pp. 123). Washington, USA: ASM Press.

Return to footnote 16 referrer

Footnote 17

World Health Organization (WHO). 1993. Disinfection and Sterilization. Laboratory Biosafety Manual (2nd ed., pp. 60-70).

Return to footnote 17 referrer

Footnote 18

Platt, J., and R. A. Bucknall. 1985. The disinfection of respiratory syncytial virus by isopropanol and a chlorhexidine-detergent handwash. J. Hosp. Infect. 6:89-94.

Return to footnote 18 referrer

Footnote 19

Krilov, L. R., and S. H. Harkness. 1993. Inactivation of respiratory syncytial virus by detergents and disinfectants. Pediatr. Infect. Dis. J. 12:582-584.

Return to footnote 19 referrer

Footnote 20

Hall, C. B., R. G. Douglas Jr., and J. M. Geiman. 1980. Possible transmission by fomites of respiratory syncytial virus. J. Infect. Dis. 141:98-102.

Return to footnote 20 referrer

Footnote 21

Jiang, X. W., Huang, T. S., Xie, L., Chen, S. Z., Wang, S. D., Huang, Z. W., Li, X. Y., and Ling, W. P. 2022. Development of a diagnostic assay by three-tube multiplex real-time PCR for simultaneous detection of nine microorganisms causing acute respiratory infections. Sci. Rep. 12:.

Return to footnote 21 referrer

Footnote 22

Cui, Y., L. Zhang, D. Hu, and Y. Yang. 2022. Antiviral and Anti-inflammatory Activity of berberine Against Respiratory Syncytial Virus Infection: an In Vitro Study. Lat. Am. J. Pharm. 41:2046-2052.

Return to footnote 22 referrer

Footnote 23

Pike, R. M. 1976. Laboratory associated infections: summary and analysis of 3921 cases. Health Laboratory Science, 13:105-114.

Return to footnote 23 referrer

Footnote 24

El Jaouhari, M., M. Striha, R. Edjoc, and S. Bonti-Ankomah. 2022. Laboratory-acquired infections in Canada from 2016 to 2021. Can Commun Dis Rep. 48:23-303-7.

Return to footnote 24 referrer

Footnote 25

Human Pathogens and Toxins Act. S.C. 2009, c. 24, 2009.

Return to footnote 25 referrer

Page details

Date modified: